Curium Receives Positive CHMP Opinion of PYLCLARI® for

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific A

If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging.Proven

Related Keywords

United States , Paris , France General , France , Ross Bethell , Pierre Curie , Benoit Woessmer , Sakir Mutevelic , Gewinn Nur , Head Of Global Communications , European Medicines Agency , Drug Administration , Committee For Medicinal Products Human Use , European Commission , Medicinal Products , Human Use , Chief Medical Officer , Marketing Authorization Application , Accurium , Eceives , Positive , Thmp , Opinion , Ylclari , Primary , Staging , Patients , Ith , Thigh , Risk , Rior , Nitial , Curative , Therapy , Olocalize , Recurrence , Suspected , Ased , Ncreasing , Serum , Prostate ,